The transition involves a strategic handover of critical products, including Cardioplegia, Total Parenteral Nutrition, and Heparin. QuVa plans to phase these medications into its existing manufacturing pipeline starting later this year, with a full integration of the portfolio expected within six months. Michael Parden, CEO of B. Braun of America—the parent company of CAPS—noted that the deal prioritizes patient care continuity and includes provisions for hiring former CAPS employees into QuVa’s operations.
QuVa Pharma Acquires 503B Product Portfolio from CAPS
As Central Admixture Pharmacy Services (CAPS) exits the 503B sterile compounding market, QuVa Pharma has stepped in to acquire the company’s essential medication portfolio, securing a supply chain that serves thousands of hospitals across the United States.
QuVa currently operates out of more than 300,000 square feet of FDA-registered manufacturing and distribution space across New Jersey, Texas, and Arizona. Stuart Hinchen, CEO of QuVa, emphasized that the acquisition aligns with the firm’s strategy to scale the production of complex, ready-to-administer medications that health systems frequently struggle to prepare reliably in-house. By absorbing the CAPS portfolio, QuVa strengthens its national footprint, currently supporting over 3,500 health system customers.
Comments (0)
No comments yet. Be the first!